BR0308184A - Composição oftálmica compreendendo ascomicina - Google Patents

Composição oftálmica compreendendo ascomicina

Info

Publication number
BR0308184A
BR0308184A BR0308184-2A BR0308184A BR0308184A BR 0308184 A BR0308184 A BR 0308184A BR 0308184 A BR0308184 A BR 0308184A BR 0308184 A BR0308184 A BR 0308184A
Authority
BR
Brazil
Prior art keywords
ascomycin
ophthalmic composition
ophthalmic
blepharitis
treatment
Prior art date
Application number
BR0308184-2A
Other languages
English (en)
Inventor
Maggy Babiole Saunier
Jean-Claude Bizec
Michelle Pik-Han Wong
Shau-Fong Yen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27791682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0308184(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0308184A publication Critical patent/BR0308184A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

"COMPOSIçãO OFTáLMICA COMPREENDENDO ASCOMICINA". A presente invenção refere-se às composições oftálmicas tópicas compreendendo uma ascomicina, por exemplo para o tratamento de doenças inflamatórias, tais como a blefarite.
BR0308184-2A 2002-03-04 2003-03-03 Composição oftálmica compreendendo ascomicina BR0308184A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36151502P 2002-03-04 2002-03-04
US40927502P 2002-09-09 2002-09-09
PCT/EP2003/002156 WO2003074054A1 (en) 2002-03-04 2003-03-03 Ophthalmic composition comprising ascomycin

Publications (1)

Publication Number Publication Date
BR0308184A true BR0308184A (pt) 2005-01-11

Family

ID=27791682

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308184-2A BR0308184A (pt) 2002-03-04 2003-03-03 Composição oftálmica compreendendo ascomicina

Country Status (28)

Country Link
US (4) US20050220823A1 (pt)
EP (1) EP1482936B1 (pt)
JP (1) JP4740542B2 (pt)
KR (1) KR100992948B1 (pt)
CN (1) CN1297270C (pt)
AR (1) AR038628A1 (pt)
AT (1) ATE341326T1 (pt)
AU (1) AU2003218679B2 (pt)
BR (1) BR0308184A (pt)
CA (1) CA2477769C (pt)
CO (1) CO5611133A2 (pt)
DE (1) DE60308836T2 (pt)
DK (1) DK1482936T3 (pt)
EC (1) ECSP045277A (pt)
EG (1) EG24403A (pt)
ES (1) ES2274214T3 (pt)
HK (1) HK1071301A1 (pt)
IL (2) IL163657A0 (pt)
MX (1) MXPA04008571A (pt)
MY (1) MY137563A (pt)
NO (1) NO20044092L (pt)
NZ (1) NZ534690A (pt)
PE (1) PE20030828A1 (pt)
PL (1) PL210870B1 (pt)
PT (1) PT1482936E (pt)
RU (1) RU2322982C2 (pt)
TW (1) TW200305437A (pt)
WO (1) WO2003074054A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2295647T3 (es) 2002-07-15 2008-04-16 Alcon, Inc. Composiciones de implante farmaceuticas lipofilas, no polimeras, para uso intraocular.
AU2003254566A1 (en) * 2002-07-23 2004-02-09 Novartis Ag Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
BRPI0705564B8 (pt) * 2007-10-10 2021-05-25 Embrapa Pesquisa Agropecuaria sistema do tipo cristal líquido contínuo contendo co-solvente portador de substâncias fracamente solúveis em água, seu processo de obtenção e seus usos
EP2238878A1 (en) 2009-04-09 2010-10-13 Nestec S.A. Beverage preparation device having a closing mechanism with force demultiplying means
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
NZ596429A (en) * 2009-05-12 2013-08-30 Galenica Ab Oil-in-water emulsion of mometasone and propylene glycol
WO2011079127A1 (en) * 2009-12-22 2011-06-30 Abbott Laboratories Abt-263 capsule
AU2011237689A1 (en) * 2010-04-07 2012-11-08 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
RU2531937C2 (ru) * 2012-05-14 2014-10-27 Открытое Акционерное Общество "Татхимфармпрепараты" Состав и способ получения глазной мази
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
AU2013384818A1 (en) * 2013-03-27 2015-11-12 Comprehensive Drug Enterprises, Ltd. Ophthalmic composition, method for preparing the same, and use of the same
US11103464B2 (en) * 2013-11-29 2021-08-31 Rohto Pharmaceutical Co., Ltd. Aqueous composition for ophthalmological use or otolaryngological use
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US10606760B2 (en) * 2017-08-23 2020-03-31 Samsung Electronics Co., Ltd. Nonvolatile memory devices and methods of controlling the same
EP3741367A1 (en) * 2019-05-21 2020-11-25 Premark Pharma GmbH Treatment of ocular disease
WO2024159768A1 (zh) * 2023-01-31 2024-08-08 温士顿医药股份有限公司 一种滴眼油剂型的医药组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE66485B1 (en) * 1989-07-05 1996-01-10 Fujisawa Pharmaceutical Co Aqueous liquid composition for external use
DE69125230T2 (de) * 1990-09-04 1997-07-10 Fujisawa Pharmaceutical Co Tricyclische Verbindungen enthaltende Salben
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
EP0656779B1 (en) * 1992-08-28 2000-04-12 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
EP0664705B1 (en) * 1993-08-18 2000-10-04 Alcon Laboratories, Inc. Compositions of ergoline derivatives for the treatment of glaucoma
CA2201134A1 (en) * 1994-10-10 1996-04-18 Alfred Sallmann Ophthalmic and aural compositions containing diclofenac potassium
CZ289773B6 (cs) * 1994-10-26 2002-04-17 Novartis Ag Farmaceutický prostředek pro místní aplikaci
FR2732598B1 (fr) * 1995-04-10 1997-05-09 Oreal Utilisation de sel de metaux alcalino-terreux pour le traitement des prurits et des dysesthesies oculaires ou palpebraux
FR2755852B1 (fr) * 1996-11-15 1998-12-24 Oreal Utilisation d'un alkylether de glycerol dans une composition cosmetique et/ou dermatologique comme actif pour le traitement de la seborrhee et de l'acne
KR100406823B1 (ko) * 1998-04-27 2003-11-21 후지사와 야꾸힝 고교 가부시키가이샤 의약 조성물
GB9826656D0 (en) * 1998-12-03 1999-01-27 Novartis Ag Organic compounds
EP1173177B2 (en) * 1999-04-30 2014-03-05 Sucampo AG Use of macrolide compounds for the treatment of dry eye

Also Published As

Publication number Publication date
TW200305437A (en) 2003-11-01
MY137563A (en) 2009-02-27
PL370917A1 (en) 2005-06-13
US20110152307A1 (en) 2011-06-23
PE20030828A1 (es) 2003-11-04
JP2005529851A (ja) 2005-10-06
NO20044092L (no) 2004-09-27
MXPA04008571A (es) 2004-12-06
US20100113501A1 (en) 2010-05-06
DE60308836T2 (de) 2007-04-26
HK1071301A1 (en) 2005-07-15
CA2477769C (en) 2011-01-18
KR20040094718A (ko) 2004-11-10
DK1482936T3 (da) 2007-01-08
US20120015971A1 (en) 2012-01-19
KR100992948B1 (ko) 2010-11-08
RU2004129593A (ru) 2005-09-10
EP1482936A1 (en) 2004-12-08
CA2477769A1 (en) 2003-09-12
ECSP045277A (es) 2004-10-26
DE60308836D1 (de) 2006-11-16
CN1638769A (zh) 2005-07-13
PT1482936E (pt) 2007-01-31
CN1297270C (zh) 2007-01-31
AU2003218679B2 (en) 2007-04-05
IL163657A (en) 2009-11-18
AR038628A1 (es) 2005-01-19
RU2322982C2 (ru) 2008-04-27
WO2003074054A1 (en) 2003-09-12
US20050220823A1 (en) 2005-10-06
NZ534690A (en) 2007-06-29
ATE341326T1 (de) 2006-10-15
EG24403A (en) 2009-04-29
IL163657A0 (en) 2005-12-18
ES2274214T3 (es) 2007-05-16
PL210870B1 (pl) 2012-03-30
AU2003218679A1 (en) 2003-09-16
JP4740542B2 (ja) 2011-08-03
EP1482936B1 (en) 2006-10-04
CO5611133A2 (es) 2006-02-28

Similar Documents

Publication Publication Date Title
BR0308184A (pt) Composição oftálmica compreendendo ascomicina
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
BRPI0512683A (pt) compostos anti-virais
MY139690A (en) Sulfonamide derivatives for the treatment of diseases.
UY29636A1 (es) 2,4-diamino-pirimidinas como inhibidores de aurora
ES2183937T3 (es) Inhibidores de la adhesion celular.
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
TW200716596A (en) Substituted amide derivatives and methods of use
CR8649A (es) Derivados de formamidina para el tratamiento de enfermedades
ATE417610T1 (de) Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
MY143390A (en) Sulfonamide derivatives for the treatment of diseases.
TNSN06228A1 (en) Compounds and methods of use
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
BR0313397A (pt) Inibidores de proteina cinase e usos destes
SE0301010D0 (sv) Novel compounds
UY29149A1 (es) Tiazolil-dihidro-indazoles
ATE490788T1 (de) Antivirale phosphonate analoge
MA32811B1 (fr) Nouveaux composés
CR10458A (es) Compuestos de triazolopirazina utiles para el tratamiento de enfermedades degenerativas e inflamatorias
SE0301009D0 (sv) Novel compounds
TW200509892A (en) Novel aminobenzophenone compounds
BRPI0413180A (pt) gorduras de baixo teor de ácido trans-groxo e composições de gorduras, e métodos de fazer as mesmas
UY28144A1 (es) Agentes terapéuticos
EA200601462A1 (ru) Соединения для лечения заболеваний

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI.A61K 31/436, A61K 47/14, A61K 47/44, A61K 31/4353, A61P 27/02

Ipc: A61K 31/436 (2011.01), A61K 47/14 (2011.01), A61K

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.